Eli Lilly will now sell cheaper vials of Zepbound, presenting a direct challenge to telehealth companies that offer compounded versions of the medication.
https://siii-clinical.com/wp-content/uploads/2021/09/Untitled-1.png00https://siii-clinical.com/wp-content/uploads/2021/09/Untitled-1.png2024-08-27 10:54:112024-08-27 10:54:11Eli Lilly’s Popular Weight Loss Drug, Zepbound, Is Getting a Price Cut
From research laboratories to clinical settings, SIII integrates the technologies, resources, and expertise our customers need to rise to the next opportunity. SIII is dedicated to exploring and researching the processes and scientific mechanisms underlying the world we live in.